{"result": {"id": "802ac557-c3d7-4446-859a-7f0f6631a535", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"PCSK9 Inhibitors and Their Therapeutic Agents\",\n    \"summary\": \"The community centers around PCSK9 Inhibitors, a class of cholesterol-lowering drugs, and includes therapeutic agents such as evolocumab, alirocumab, toleisumab, and inclisiran. These entities are interconnected through their roles in inhibiting the PCSK9 protein to manage hypercholesterolemia and related conditions, highlighting their clinical significance and multifaceted therapeutic benefits.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the critical role of PCSK9 inhibitors in managing cardiovascular diseases and their inclusion in clinical guidelines.\",\n    \"findings\": [\n        {\n            \"summary\": \"PCSK9 Inhibitors as a pivotal class of drugs\",\n            \"explanation\": \"PCSK9 Inhibitors represent a crucial class of drugs in the management of hypercholesterolemia and related cardiovascular conditions. Their mechanism of action, which involves inhibiting the PCSK9 protein to enhance LDL-C clearance, underscores their therapeutic value. The inclusion of these inhibitors in clinical guidelines further emphasizes their importance in modern medicine. [Data: Entities (2991), Relationships (4798, 4799, 4800, 4801)]\"\n        },\n        {\n            \"summary\": \"Evolocumab's role in the PCSK9 inhibitor community\",\n            \"explanation\": \"Evolocumab is a monoclonal antibody that serves as a key therapeutic agent within the PCSK9 inhibitor community. Its administration every 2 or 4 weeks offers a practical treatment option for patients, contributing to the community's overall impact on cardiovascular health management. [Data: Entities (4549), Relationships (4798)]\"\n        },\n        {\n            \"summary\": \"Alirocumab's contribution to cholesterol management\",\n            \"explanation\": \"Alirocumab, another monoclonal antibody targeting PCSK9, plays a significant role in the community by providing an effective means to lower cholesterol levels. Its bi-weekly administration schedule adds to the variety of treatment options available within this therapeutic class. [Data: Entities (4550), Relationships (4799)]\"\n        },\n        {\n            \"summary\": \"Toleisumab's flexible dosing options\",\n            \"explanation\": \"Toleisumab offers flexibility in dosing schedules, with administration possible every 2, 4, or 6 weeks. This adaptability enhances patient compliance and treatment efficacy, marking its importance within the PCSK9 inhibitor community. [Data: Entities (4551), Relationships (4800)]\"\n        },\n        {\n            \"summary\": \"Inclisiran's innovative approach to PCSK9 inhibition\",\n            \"explanation\": \"Inclisiran introduces a novel mechanism of action by targeting PCSK9 synthesis through siRNA technology. Its approval in China for treating hypercholesterolemia and mixed dyslipidemia highlights the expanding therapeutic potential of PCSK9 inhibitors. [Data: Entities (4552), Relationships (4801)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752168574, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 640, "prompt_tokens": 2540, "total_tokens": 3180, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1472}, "prompt_cache_hit_tokens": 1472, "prompt_cache_miss_tokens": 1068}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        },\n        {\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        },\n        {\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        },\n        {\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }\n    ]\n}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n2991,PCSK9 INHIBITORS,\"**PCSK9 Inhibitors** are a class of cholesterol-lowering drugs referenced in clinical guidelines. These drugs, which include **evolocumab**, **alirocumab**, and **toleisumab**, function by inhibiting the PCSK9 protein, thereby increasing the number of LDL receptors on cell membranes. This mechanism enhances the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream, leading to significant reductions in LDL-C levels.  \n\nBeyond their primary role in cholesterol management, PCSK9 inhibitors exhibit additional therapeutic effects, such as stabilizing atherosclerotic plaques, anticoagulation, and anti-inflammatory properties. These multifaceted benefits contribute to their potential in reducing cardiovascular risk.  \n\nIn summary, PCSK9 inhibitors are a clinically recognized class of drugs that effectively lower LDL-C while offering secondary cardiovascular protective effects. Their inclusion in treatment guidelines underscores their importance in managing hypercholesterolemia and related conditions.\",6\r\n4549,EVOLOCUMAB,\"Evolocumab is a PCSK9 monoclonal antibody used to lower cholesterol levels, administered subcutaneously every 2 or 4 weeks.\"\"\",1\r\n4550,ALIROCUMAB,\"Alirocumab is a PCSK9 monoclonal antibody used to lower cholesterol levels, administered subcutaneously every 2 weeks.\"\"\",1\r\n4551,TOLEISUMAB,\"Toleisumab is a PCSK9 monoclonal antibody used to lower cholesterol levels, administered subcutaneously every 2, 4, or 6 weeks.\"\"\",1\r\n4552,INCLISIRAN,\"Inclisiran is a small interfering RNA (siRNA) targeting PCSK9, approved in China in August 2023 for treating primary hypercholesterolemia and mixed dyslipidemia in adults.\"\"\",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\r\n4798,PCSK9 INHIBITORS,EVOLOCUMAB,Evolocumab is a type of PCSK9 inhibitor,7\r\n4799,PCSK9 INHIBITORS,ALIROCUMAB,Alirocumab is a type of PCSK9 inhibitor,7\r\n4800,PCSK9 INHIBITORS,TOLEISUMAB,Toleisumab is a type of PCSK9 inhibitor,7\r\n4801,PCSK9 INHIBITORS,INCLISIRAN,Inclisiran targets PCSK9 synthesis to lower LDL-C levels,7\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_a40a13b55864d0288c57ad364a6e4e67ab13664b22cbbab873877b4f78790152_v2"}